Membrane-bound and soluble IL-15/IL-15Rα complexes display differential signaling and functions on human hematopoietic progenitors

Blood

Volumn 106, Issue 7, 2005, Pages 2302-2310

  Giron Michel, Julien ^b   Giuliani, Massimo ^b   Fogli, Manuela ^b   Brouty Boýe, Danièle ^b   Ferrini, Silvano ^b   Baychelier, Florence ^b   Eid, Pierre ^b   Lebousse Kerdilès, Caroline ^b   Durali, Deniz ^b   Biassoni, Roberto ^b   Charpentier, Bernard ^b   Vasquez, Aimé ^b   Chouaib, Salem ^b   Caignard, Anne ^b   Moretta, Lorenzo ^b   Azzarone, Bruno ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR; STAT6 PROTEIN;

ARTICLE; BLOOD; CELL INTERACTION; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 27144446158     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-01-0064     Document Type: Article

References (44)

1. Waldmann TA. The IL-2/IL-15 receptor systems: targets for immunotherapy. J Clin Immunol. 2002;22:51-56.
2. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97:14-32.
3. Lodolce J, Burkett P, Koka R, et al. Interleukin-15 and the regulation of lymphoid homeostasis. Mol Immunol. 2002;3:537-544.
4. Zambello R, Facco M, Trentin L, et al. Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Blood. 1997;89:201-211.
5. Musso T, Colosso L, Zucca M, et al. Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood. 1999;93:3531-3539.
6. Rappl G, Kapsokefalou A, Heuser C, et al. Dermal fibroblasts sustain proliferation of activated T cells via membrane-bound interleukin-15 upon long-term stimulation with tumor necrosis factoralpha. J Invest Dermatol. 2001;116:102-109.
7. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity. 2002;17:537-547.
8. Lodolce JP, Boone DL, Chai S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity. 1998;9:669-676.
9. Kennedy MK, Glaccum M, Brown SN, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med. 2000;191:771-780.
10. Ruckert R, Brandt K, Bulanova E, Mirghomizadeh F, Paus R, Bulfone-Paus S. Dendritic cell-derived IL-15 controls the induction of CD8 T cell immune responses. Eur J Immunol. 2003;33:3493-3503.
11. Koka R, Burkett PR, Chien M, et al. Interleukin (IL)-15Rα-deficient natural killer cells survive in normal but not IL-15R-deficient mice. J Exp Med. 2003;197:977-984.
12. Mrozek E, Anderson P, Caligiuri MA. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood. 1996; 8:2632-2640.
13. Yu H, Fehniger TA, Fuchshuber P, et al. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Blood. 1998;92:3647-3657.
14. Carayol G, Robin C, Bourhis JH, et al. NK cells differentiated from bone marrow, cord blood and peripheral blood stem cells exhibit similar phenotype and functions. Eur J Immunol. 2002 ;28:1991-2002.
15. Puzanov IJ, Williams NS, Schatzle J, Sivakumar PV, Bennett M, Kumar V. Ontogeny of NK cells and the bone marrow microenvironment: where does IL-15 fit in? Res Immunol. 1997;148:195-201.
16. Brouty-Boye D, Doucet C, Clay D, Le Bousse-Kerdiles MC, Lampidis TJ, Azzarone B. Phenotypic diversity in human fibroblasts from myelometaplasic and non-myelometaplasic hematopoietic tissues. Int J Cancer. 1998;76:767-773.
17. Brouty-Boye D, Briard D, Azzarone B, et al. Effects of human fibroblasts from myelometaplasic and non-myelometaplasic hematopoietic tissues on CD34+ stem cells. Int J Cancer. 2001;92:484-488.
18. Briard D, Brouty-Boye D, Azzarone B, Jasmin C. Fibroblasts from human spleen regulate NK cell differentiation from blood CD34(+) progenitors via cell surface IL-15. J Immunol. 2002;168:4326-4332.
19. Briard D, Brouty-Boye D, Giron-Michel J, Azzarone B, Jasmin C, Le Bousse-Kerdiles C. Impaired NK cell differentiation of blood-derived CD34+ progenitors from patients with myeloid metaplasia with myelofibrosis. Clin Immunol. 2003;10:201-212.
20. Cohen Y, Nagler A. Cord blood biology and transplantation. Isr Med Assoc J. 2004;6:39-46.
21. Giron-Michel J, Fogli M, Gaggero A, et al. Detection of a functional hybrid receptor gammac/GM-CSFRbeta in human hematopoietic CD34+ cells. J Exp Med. 2003;197:763-775.
22. Farner NL, Gan J, de Jong JL, et al. Alteration of the CD34+ Tf-1 beta cell line profile in response to longterm exposure to IL-15. Cytokine. 1997;9:316-327.
23. Meazza R, Basso S, Gaggero A, et al. Interleukin (IL)-15 induces survival and proliferation of the growth factor-dependent acute myeloid leukemia M-07e through the IL-2 receptor beta/gamma. Int J Cancer. 1998;78:189-195.
24. Gisselbrecht S. The CIS/SOCS proteins: a family of cytokine-inducible regulators of signaling. Eur Cytokine Netw. 1999;10:463-470.
25. de Groot RP, Raaijmakers JA, Lammers JW, Koenderman L. STAT5-dependent cyclin D1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun. 2000;3:299-305.
26. Bernard J, Harb C, Mortier E, et al. Identification of an interleukin-15alpha receptor-binding site on human interleukin-15. J Biol Chem. 2004;279:24313-24322.
27. Budagian V, Bulanova E, Orinska Z, et al. Reverse signaling through membrane-bound interleukin-15. J Biol Chem. 2004;279:42192-42201.
28. Neely GG, Epelman S, Ma LL, et al. Monocyte surface-bound IL-15 can function as an activating receptor and participate in reverse signaling. J Immunol. 2004;172:4225-4234.
29. Selvaraj NG, Omi E, Gibori G, Rao MC. Janus kinase 2 (JAK2) regulates prolactin-mediated chloride transport in mouse mammary epithelial cells through tyrosine phosphorylation of Na+K+-2Cl- cotransporter. Mol Endocrinol. 2000;14:2054-2065.
30. Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15 Immunity. 1998;8:591-599.
31. Azzarone B, Suarez H, Mingari MC, Moretta L, Fauci AS. 4F2 monoclonal antibody recognizes a surface antigen on spread human fibroblasts of embryonic but not of adult origin. J Cell Biol. 1984;98:1133-1137.
32. Azzarone B, Eid P, Malpiece Y, Andeol Y, Fauci AS, Suarez H. Evolution in the structure and distribution of 4F2-antigen from the oncofetal to the adult phenotype of human fibroblasts. Int J Cancer. 1986;38:177-181.
33. Daya-Grosjean L, Azzarone B, Maunoury R, et al. SV40 immortalization of adult human mesenchymal cells from neuroretina: biological, functional and molecular characterization. Int J Cancer. 1984;33:319-329.
34. Giron-Michel J, Caignard A, Fogli M, et al. Differential STAT3, STAT5, and NF-kappaB activation in human hematopoietic progenitors by endogenous interleukin-15: implications in the expression of functional molecules. Blood. 2003;10:109-117.
35. Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connections maps. Science. 2003;300:1527-1538.
36. Masuda A, Matsuguchi T, Yamaki K, et al. Interleukin-15 induces rapid tyrosine phosphorylation of STAT6 and the expression of interleukin-4 in mouse mast cells. J Biol Chem. 2000;275:29331-29337.
37. Bulanova E, Budagian V, Orinska Z, Krause H, Paus R, Bulfone-Paus S. Mast cells express novel functional IL-15 receptor alpha isoforms. J Immunol. 2003;170:5045-5055.
38. Smithgall TE, Briggs SD, Schreiner S, Lerner EC, Cheng H, Wilson MB. Control of myeloid differentiation and survival by Stats. Oncogene. 2000;19:2612-2618.
39. Bunting KD, Yu WM, Bradley HL, et al. Increased numbers of committed myeloid progenitors but not primitive hematopoietic stem/progenitors in mice lacking STAT6 expression. J Leukoc Biol. 2004;76:484-490.
40. Cohney SJ, Sanden D, Cacalano NA, et al. SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol Cell Biol. 1999;19:4980-4988.
41. Croker BA, Metcalf D, Robb L, et al. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity. 2004;20:153-165.
42. Marine JC, McKay C, Wang D, et al. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell. 1999;98:617-627.
43. Anderson P, Sundstedt A, Li L, et al. Differential activation of signal transducer and activator of transcription (STAT)3 and STAT5 and induction of suppressors of cytokine signalling in T(h)1 and T(h)2 cells. Int Immunol. 2003;15:1309-1317.
44. Mortier E, Bernard J, Plet A, Jacques Y. Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol. 2004;173:1681-1688.